Viral Oncology Career Development Grant

病毒肿瘤学职业发展补助金

基本信息

项目摘要

DESCRIPTION (provided by applicant): I have reached a point in my career that requires singular dedication to my area of interest, viral oncology. Since my fellowship, I have been interested in lymphomas associated with viruses. There are many patients with these diseases at our medical center. HIV related lymphomas are common and Miami is an endemic area for HTLV-I therefore, Adult T Cell Leukemia is frequently seen. We have one of the largest organ transplant programs and there are many cases of post transplant lymphoproliferative disease. My emphasis has been on experimental therapeutics, specifically how certain viral lymphomas undergo apoptosis in response to antiviral agents. This work has resulted in promising treatments for viral lymphomas. I have continued to investigate the mechanisms of activity of these agents in the clinic and in the laboratory. We have found that distinct apoptotic pathways are activated by the antiviral agents Azidothymidine and Interferon alpha in herpes-virus Lymphomas. We are now investigating the cellular and viral factors which dictate sensitivity or resistance. My other area of interest is training physicians in the area of viral oncology. My training grant has allowed me to attract bright young M.D.'s and M.D./Ph.D.'s to this field. Each of the fellows is studying a specific area of viral oncology. Since Miami is the gateway to the Caribbean and South America, I plan to develop collaborations with these areas hard hit by AIDS and AIDS related cancers. I will also utilize a training program for African physicians interested in viral oncology. We have established infrastructures to undertake these tasks. The environment for career development is excellent. My superiors have agreed to free me of all duties unrelated to research, mentorship, and career development. Perhaps no other medical center could offer such a diverse clinical population. I am supported by clinical and basic peer reviewed funds and the cancer center as a program leader. I have also developed collaborations with our top scientists to further strengthen my program. My immediate career goal is to determine the mechanisms to antiviral mediated apoptosis in AIDS Lymphomas and develop the clinical and educational components of our viral oncology program. My long term goal is to develop our viral oncology program to where we are recognized for clinical care and research excellence and extend our studies to Latin America and Africa. My role as mentor is ongoing.
描述(由申请人提供):在我的职业生涯中,我已经达到了一个点

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William J Harrington其他文献

The use of high-dose azidothymidine in combination with chemotherapy upfront is an effective treatment approach for gamma-herpes virus-related non-Hodgkin’s lymphomas
  • DOI:
    10.1186/1750-9378-5-s1-a81
  • 发表时间:
    2010-10-11
  • 期刊:
  • 影响因子:
    2.800
  • 作者:
    Ulas Darda Bayraktar;Eileen Bernal;Lisa Cabral;William J Harrington;Dirk P Dittmer;Juan Carlos Ramos
  • 通讯作者:
    Juan Carlos Ramos

William J Harrington的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William J Harrington', 18)}}的其他基金

Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7289830
  • 财政年份:
    2006
  • 资助金额:
    $ 13.69万
  • 项目类别:
University of Miami
迈阿密大学
  • 批准号:
    7130723
  • 财政年份:
    2006
  • 资助金额:
    $ 13.69万
  • 项目类别:
Targeted Therapy for Burkitt Lymphoma in Resource Poor Settings
资源匮乏地区伯基特淋巴瘤的靶向治疗
  • 批准号:
    7288752
  • 财政年份:
    2006
  • 资助金额:
    $ 13.69万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7097879
  • 财政年份:
    2006
  • 资助金额:
    $ 13.69万
  • 项目类别:
Targeted Therapy for Burkitt Lymphoma in Resource Poor Settings
资源匮乏地区伯基特淋巴瘤的靶向治疗
  • 批准号:
    7121431
  • 财政年份:
    2006
  • 资助金额:
    $ 13.69万
  • 项目类别:
Viral Oncology Career Development Grant
病毒肿瘤学职业发展补助金
  • 批准号:
    6934666
  • 财政年份:
    2001
  • 资助金额:
    $ 13.69万
  • 项目类别:
Viral Oncology Career Development Grant
病毒肿瘤学职业发展补助金
  • 批准号:
    6649857
  • 财政年份:
    2001
  • 资助金额:
    $ 13.69万
  • 项目类别:
Viral Oncology Career Development Grant
病毒肿瘤学职业发展补助金
  • 批准号:
    6522802
  • 财政年份:
    2001
  • 资助金额:
    $ 13.69万
  • 项目类别:
Viral Oncology Career Development Grant
病毒肿瘤学职业发展补助金
  • 批准号:
    6333297
  • 财政年份:
    2001
  • 资助金额:
    $ 13.69万
  • 项目类别:
Antiviral Mediated Apoptosis of Non-Hodgkin's Lymphoma
抗病毒介导的非霍奇金淋巴瘤细胞凋亡
  • 批准号:
    6734649
  • 财政年份:
    2000
  • 资助金额:
    $ 13.69万
  • 项目类别:

相似海外基金

Epstein-Barr virus and B-cell co-opted functions of the endogenous retrovirus envelope protein, Syncytin-1
Epstein-Barr 病毒和 B 细胞共同选择内源性逆转录病毒包膜蛋白 Syncytin-1 的功能
  • 批准号:
    10490258
  • 财政年份:
    2021
  • 资助金额:
    $ 13.69万
  • 项目类别:
Regulation of host miRNA activity by Epstein-Barr virus BHRF1
Epstein-Barr 病毒 BHRF1 对宿主 miRNA 活性的调节
  • 批准号:
    10170258
  • 财政年份:
    2020
  • 资助金额:
    $ 13.69万
  • 项目类别:
Regulation of host miRNA activity by Epstein-Barr virus BHRF1
Epstein-Barr 病毒 BHRF1 对宿主 miRNA 活性的调节
  • 批准号:
    10039435
  • 财政年份:
    2020
  • 资助金额:
    $ 13.69万
  • 项目类别:
Binding of Epstein Barr Virus EBNA2 Unifies Multiple Sclerosis Genetic Mechanisms
EB 病毒 EBNA2 的结合统一了多发性硬化症的遗传机制
  • 批准号:
    10657035
  • 财政年份:
    2017
  • 资助金额:
    $ 13.69万
  • 项目类别:
Targeting Apoptosis and Immune Control of Epstein-Barr Virus Infected Tonsillar B Cells
针对 Epstein-Barr 病毒感染的扁桃体 B 细胞的凋亡和免疫控制
  • 批准号:
    9237256
  • 财政年份:
    2016
  • 资助金额:
    $ 13.69万
  • 项目类别:
Temporal regulation of the essential Epstein-Barr virus oncoprotein LMP1
EB 病毒必需癌蛋白 LMP1 的时间调控
  • 批准号:
    8594953
  • 财政年份:
    2013
  • 资助金额:
    $ 13.69万
  • 项目类别:
Temporal regulation of the essential Epstein-Barr virus oncoprotein LMP1
EB 病毒必需癌蛋白 LMP1 的时间调控
  • 批准号:
    8727986
  • 财政年份:
    2013
  • 资助金额:
    $ 13.69万
  • 项目类别:
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
调节 Epstein-Barr 病毒介导的 B 细胞生长转化的宿主途径
  • 批准号:
    9300875
  • 财政年份:
    2011
  • 资助金额:
    $ 13.69万
  • 项目类别:
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
调节 Epstein-Barr 病毒介导的 B 细胞生长转化的宿主途径
  • 批准号:
    9976477
  • 财政年份:
    2011
  • 资助金额:
    $ 13.69万
  • 项目类别:
Genetic and Proteomic Analysis of Epstein-Barr Virus LMP1 Activation of NF-kB
EB 病毒 LMP1 激活 NF-kB 的遗传和蛋白质组学分析
  • 批准号:
    8284169
  • 财政年份:
    2010
  • 资助金额:
    $ 13.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了